Independent Working Group · AIPATH
Artificial Intelligence in Pathology
Adoption of digital pathology (DP) and AI applications in oncopathology for improved patient outcomes in cancer care, education, training of the workforce and translational research.
- Status
- Active
- Operational since
- 2025
- Group type
- Independent Working Group (IWG)
On this page
Purpose
The purpose of the Artificial Intelligence in Pathology (AIPATH) IWG is to enable applications of AI in pathology at every step of the journey of tissue — from laboratory workflow, viz. sample acquisition and processing, to offering diagnosis, determining prognosis, predictive analytics, and analysing and integrating enormous and complex datasets across the various diagnostic divisions of pathology.
Objective & scope
Adoption of digital pathology (DP) and AI applications in oncopathology for improved patient outcomes in cancer care, education, training of the workforce and translational research.
We aim
- To seamlessly integrate state-of-the-art DP technologies into cancer care.
- To foster collaboration, innovation and responsible implementation of digital solutions in oncopathology.
- To create and facilitate awareness, and impart education about the adoption of DP and AI applications in oncopathology.
Leadership
Initial leadership team
Dr. Sangeeta Desai
Co-Lead 1
Dr. Rajiv Kaushal
Co-Lead 2
- Term for the Co-Chairs would be 2 years, but the board can decide on an extended term for multi-year projects.
- Additional advisors will be finalised after board review.
Stakeholder ecosystem
Open membership
- Clinicians
- Hospital informatics leads
- EMR providers
- Researchers & AI scientists
- Government agencies
Core members
Dr Om Shree Shetty
Scientific Officer, Molecular Pathology, Tata Memorial Hospital, Mumbai
Dr Gurudatt Gupta
Head, Pathology, RGICRC, New Delhi
Dr Anila Sharma
Senior Consultant, RGICRC, New Delhi
Dr Paromita Roy
Senior Consultant & Head, Pathology, Tata Medical Center, Kolkata
Dr Sangeetha Nayanar
Professor, Pathology, Malabar Cancer Centre, Kerala
Dr Kirti Chadha
Chief Scientific & Innovation Officer & Chief Oncopathologist, Metropolis Healthcare Ltd
Subject-matter experts (by invitation)
Dr Ujjwal Baid
Director of Research, Emory University, Atlanta, USA
Ms Anuradha Dihingia
Manager, Partnering & AI Pathology Lab Division, Roche Diagnostics India Pvt. Ltd
Planned activities
These are the group’s planned activities and targets. They are plans, not completed results.
Short term
0–12 months
- Collaborate with 3 pathology departments (digital pathology–ready) for pilot projects.
- Develop algorithms for 2 common cancer types and/or workflow integration across pathology divisions.
Medium term
12–24 months
- Implement pilots across 3 departments.
- Publish early findings and recommendations.
Long term
3–5 years
- Build a scalable model adopted by at least 5 institutions.
- Expand through international collaborations and global standards alignment.